|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Cell Biology,3 Institute of Biology–UNICAMP, 13084-864 Campinas, Brazil
Rio Preto Universitary Center–UNIRP,5 Biological Sciences and Veterinary Medicine School, 15025-400 São José do Rio Preto, São Paulo, Brazil
Laboratory of Microscopy and Microanalysis,4 Department of Biology, São Paulo State University–UNESP/IBILCE, 15054-000 São José do Rio Preto, São Paulo, Brazil
ABSTRACT
The present work aims to evaluate the response of the adult gerbil female prostate (paraurethral glands) and ovaries to short-term exposure to antiestrogenic agents, consisting of daily oral doses of letrozole (1 mg kg–1 day–1) or intradermal doses of tamoxifen (1 mg/kg) every other day for 21 days. The serum levels of testosterone and estradiol were monitored, and the prostates and ovaries collected for structural, ultrastructural, and immunocytochemical analyses. The letrozole treatment resulted in increases of serum testosterone levels and secretory activity as well as in glandular hyperplasia and dysplastic growth, simulating the effects caused by the exogenous androgens. The effects caused by tamoxifen indicate that this endocrine agent acted as an estrogenic agonist on the prostate, causing glandular hypertrophy, secretory activity decrease, and the development of prostatic lesions. Therefore, it is possible to conclude that the letrozole and tamoxifen therapies result in a series of complex effects that endanger the physiology of hormone-dependent organs, including the female prostate and ovaries. The hormonal imbalance caused by administration of these drugs resulted in considerable changes in prostatic morphology, in a manner very similar to what occurs during the development of prostatic lesions in aged postmenopausal women. Thus, these therapies must be chosen carefully since long-term treatments can result in female prostate dysplasic lesions.
androgens, estradiol, female prostate, female reproductive tract, letrozole, morphology, ovary, prostate, tamoxifen
1Supported by National Council of Scientific and Technological Development (CNPq; Proc. No. 301111/05-7 research fellowship to S.R.T.) and São Paulo State Research Foundation (FAPESP; Proc. No. 02/12942-6). This paper is part of the thesis presented by FCAS to the Institute of Biology, UNICAMP, in partial fulfillment of the requirement for a PhD degree.
Correspondence: 2Sebastião Roberto Taboga, Departamento de Biologia–IBILCE/UNESP–Rua Cristóvão Colombo, 2265, Jardim Nazareth, São José do Rio Preto, SP, Brazil, 15054-000. FAX: 55 17 32212390; e-mail: taboga{at}ibilce.unesp.br
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |